Aligos Therapeutics, Inc. Deal History & Licensing Activity
Aligos Therapeutics, Inc. is a biotech headquartered in US. Over the past three years, Aligos Therapeutics, Inc. has been involved in 2 licensing and acquisition transactions, with a primary focus on Oligonucleotides (2 deals). The company currently has 4 active clinical trials, primarily in Infectious Disease.
Deals (12mo)
2
Active Trials
4
Top Modality
Oligonucleotides
Focus Area
Infectious Disease
Aligos Therapeutics, Inc. Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Aligos Therapeutics, Inc. in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| pevifoscorvir sodium | Amoytop Biotech | Oligonucleotides | Preclinical | collaboration | Apr 21, 2026 |
| pevifoscorvir sodium | Xiamen Amoytop Biotech Co., Ltd. | Small Molecules | Phase 2 | license | Apr 16, 2026 |
Aligos Therapeutics, Inc. Pipeline Focus
Therapeutic areas and modalities where Aligos Therapeutics, Inc. is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Aligos Therapeutics, Inc. Strategic Signals
Key indicators of Aligos Therapeutics, Inc.'s licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Aligos Therapeutics, Inc. Clinical Pipeline
Aligos Therapeutics, Inc. has 4 active clinical trials across 2 development phases.
1
Phase 1
3
Phase 2
See How Your Asset Matches Aligos Therapeutics, Inc.'s Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Infectious Disease assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Infectious Disease Deal Benchmarks
Market sizing, deal terms, and competitive landscape for infectious disease
Oligonucleotides Benchmarks
Upfront, milestone, and royalty benchmarks for oligonucleotides deals
Small Molecules Benchmarks
Upfront, milestone, and royalty benchmarks for small molecules deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Aligos Therapeutics, Inc. Licensing & Deal Activity
Aligos Therapeutics, Inc. is a biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 2 deals over the past three years, Aligos Therapeutics, Inc. ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Aligos Therapeutics, Inc. include Infectious Disease (4 deals and trials), and Infectious (2 deals and trials). In terms of modality, Aligos Therapeutics, Inc. has shown particular interest in oligonucleotides, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Aligos Therapeutics, Inc. and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Aligos Therapeutics, Inc.'s historical deal terms, or explore all company profiles to find the best partner match for your pipeline.